The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

Drugs such as Padcev, Kadcyla, and Enhertu are leading the market, showcasing the therapeutic viability of ADCs. The substantial growth in ADC sales underscores their potential in offering ...